title: [Development of brain atrophy, therapy and therapy monitoring in glutaric aciduria type I (glutaryl-CoA dehydrogenase deficiency)].
abstract: Serial trans-fontanellar sonographic examination in a patient with glutaric aciduria type I (GA I) demonstrated that the typical frontotemporal cerebral atrophy developed postnatally within three months paralleling the onset of dystonic symptoms. Pathogenesis of the accompanying macrocephaly remains unclear and can form a diagnostic pitfall. Diet low in lysine and tryptophan led to a dramatic fall in urinary glutaric acid (GA) excretion but as in other patients with GA I did not substantially influence clinical symptoms and course. We determined unchanged levels of GA in plasma and cerebrospinal fluid resulting from variable renal tubular secretion and reabsorption of GA. Monitoring urinary excretion of GA appears inappropriate to control dietary treatment in GA I. Substitutive correction of secondary carnitine depletion seems to protect from deleterious metabolic crises. Treatment with valproic acid resulted in a rise of GABA-concentration in cerebrospinal fluid but did not ameliorate clinical symptoms. This finding is in contrast with the hypothesis that inhibition of cerebral GABA-synthesis by GA is responsible for the development of dystonia in GA 1. Although we observed impressing fluctuation of dystonic symptoms, levodopa did not show therapeutic effects. The extreme variability in the severity of neurologic disease in metabolically identical individuals leads to a "two-hit"-hypothesis.
authors.affiliation: Kinderklinik, Städt. Kliniken Kassel.
authors.forename: B
authors.initials: B
authors.lastname: Lawrenz-Wolf
authors.forename: K P
authors.initials: KP
authors.lastname: Herberg
authors.forename: G F
authors.initials: GF
authors.lastname: Hoffmann
authors.forename: D H
authors.initials: DH
authors.lastname: Hunneman
authors.forename: W
authors.initials: W
authors.lastname: Lehnert
authors.forename: F
authors.initials: F
authors.lastname: Hanefeld
mesh_terms: D000592:Amino Acid Metabolism, Inborn Errors / Q000175:diagnosis* / Q000235:genetics / Q000628:therapy; D001418:Baclofen / Q000008:administration & dosage; D001921:Brain / Q000473:pathology*; D001928:Brain Diseases, Metabolic / Q000175:diagnosis* / Q000235:genetics / Q000628:therapy; D002331:Carnitine / Q000008:administration & dosage; D002508:Cephalometry; D002675:Child, Preschool; D003131:Combined Modality Therapy; D003241:Consanguinity; D004453:Echoencephalography; D005260:Female; D005977:Glutarates / Q000652:urine*; D050770:Glutaryl-CoA Dehydrogenase; D006801:Humans; D007223:Infant; D007980:Levodopa / Q000008:administration & dosage; D008239:Lysine / Q000008:administration & dosage; D010088:Oxidoreductases / Q000172:deficiency*; D044925:Oxidoreductases Acting on CH-CH Group Donors; D014057:Tomography, X-Ray Computed; D014364:Tryptophan / Q000008:administration & dosage; D014635:Valproic Acid / Q000008:administration & dosage; D005680:gamma-Aminobutyric Acid / Q000134:cerebrospinal fluid
chemical_list: D005977:Glutarates; D007980:Levodopa; D005680:gamma-Aminobutyric Acid; D014635:Valproic Acid; D014364:Tryptophan; D010088:Oxidoreductases; D044925:Oxidoreductases Acting on CH-CH Group Donors; D050770:Glutaryl-CoA Dehydrogenase; D001418:Baclofen; C035736:glutaric acid; D008239:Lysine; D002331:Carnitine